Effects of a Resistance Training Period on Blood Pressure of Hypertensive Elderlies: Influence of the Polymorphism of the Angiotensin Converting Enzyme

October 11, 2013 updated by: Alessandra Medeiros, Federal University of São Paulo
The study aimed to evaluate the chronic effects of resistance training on blood pressure and biochemical exams in hypertensive elderlies and the influence of the polymorphism of the angiotensin converting enzyme in these response.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

To investigate the chronic effects of resistance training on blood pressure and biochemical exams in elderly, 135 hypertensive elderlies were divided into 2 groups: trained and control. The trained group was submitted to a resistance training period. Before the 16 weeks ACE gene was genotyped (PCR). Before and after 16 weeks, blood pressure (ambulatory), HDL-cholesterol, Total cholesterol, Glycemia, Triacylglycerol (colorimetric assay) and plasminogen activator inhibition (PAI-1), intercellular adhesion molecule (ICAM-1), vascular endothelial cell adhesion molecule (VCAM-1), Adiponectin, tumor necrosis factor alpha (TNF-alpha), C Reactive Protein, Angiotensin II, Angiotensin Converting Enzyme, Angiotensin 1-7, (ELISA assay) were measured.

Study Type

Interventional

Enrollment (Actual)

136

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • SP
      • Santos, SP, Brazil
        • UNIMED

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Hypertensives
  • Age 60 to 85 years
  • Nonactive

Exclusion Criteria:

  • Orthopedic problems or other problem that prevented the exercises
  • Change in drug treatment during protocol
  • Absence in more than 25% of the exercise sessions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
Experimental: Resistance training
Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
Behavioral: Resistance training
Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood Pressure
Time Frame: 16 weeks
Blood pressure was measured by Ambulatorial Monitoring Blood Pressure before and after 16 weeks of intervention.
16 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
HDL-cholesterol
Time Frame: 16 weeks
HDL-cholesterol was analyzed by colorimetric assay, before and after 16 weeks of intervention.
16 weeks
Total Cholesterol
Time Frame: 16 weeks
Total cholesterol was analyzed by colorimetric assay, before and after 16 weeks of intervention.
16 weeks
Glycemia
Time Frame: 16 weeks
Glycemia was analyzed by colorimetric assay, before and after 16 weeks of intervention.
16 weeks
Triacylglycerol
Time Frame: 16 weeks
Triacylglycerol was analyzed by colorimetric assay, before and after 16 weeks of intervention.
16 weeks
PAI-1
Time Frame: 16 weeks
PAI-1 was analyzed by ELISA assay, before and after 16 weeks of intervention.
16 weeks
ICAM-1
Time Frame: 16 weeks
ICAM-1 was analyzed by ELISA assay, before and after 16 weeks of intervention.
16 weeks
VCAM-1
Time Frame: 16 weeks
VCAM-1 was analyzed by ELISA assay, before and after 16 weeks of intervention.
16 weeks
Adiponectin
Time Frame: 16 weeks
Adiponectin was analyzed by ELISA assay, before and after 16 weeks of intervention.
16 weeks
TNF alpha
Time Frame: 16 weeks
TNF alpha was analyzed by ELISA assay, before and after 16 weeks of intervention.
16 weeks
C Reactive Protein
Time Frame: 16 weeks
C Reactive Protein was analyzed by ELISA assay, before and after 16 weeks of intervention.
16 weeks
Angiotensin II
Time Frame: 16 weeks
Angiotensin II was analyzed by ELISA assay, before and after 16 weeks of intervention.
16 weeks
Angiotensin Converting Enzyme
Time Frame: 16 weeks
Angiotensin Converting Enzyme was analyzed by ELISA assay, before and after 16 weeks of intervention.
16 weeks
Angiotensin 1-7
Time Frame: 16 weeks
Angiotensin 1-7 was analyzed by ELISA assay, before and after 16 weeks of intervention.
16 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Federal University of São Paulo

Collaborators

Fundação de Amparo à Pesquisa do Estado de São Paulo

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2010

Primary Completion (Actual)

April 1, 2013

Study Completion (Actual)

April 1, 2013

Study Registration Dates

First Submitted

October 9, 2013

First Submitted That Met QC Criteria

October 11, 2013

First Posted (Estimate)

October 16, 2013

Study Record Updates

Last Update Posted (Estimate)

October 16, 2013

Last Update Submitted That Met QC Criteria

October 11, 2013

Last Verified

October 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ACE RT

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on Resistance training

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe